An investigational HMSC-derived exosome biologic with RNA-seq confirmed enrichment of neuroprotective and immunomodulatory cargo. Cryo-formed ExoPearl™ format. Characterised per batch. Supplied exclusively to licensed practitioners and verified research institutions.
Every BEXO·NEURO vial is characterised per batch with NTA, TEM, and RNA-seq. Full documentation supplied with each order.
Peer-reviewed literature documents investigational interest in HMSC-derived exosomes across the following domains. BEXO·NEURO is characterised to confirm cargo relevance to each area.
For research institutions investigating HMSC-EV biology, signalling pathways, and cargo characterisation. Every BEXO·NEURO batch includes full RNA-seq data, NTA particle distribution, and TEM imaging - enabling reproducible downstream analysis without additional characterisation overhead.
Peer-reviewed literature documents investigational interest in HMSC-derived exosomes for M1→M2 macrophage transition, Th17 suppression, and Treg promotion. Evidence spans rheumatoid arthritis, SLE, and T1DM models. miR-146a - confirmed per batch via RNA-seq - is the key cargo mediator identified in this literature.
Peer-reviewed literature documents investigational interest in HMSC-derived exosomes for neuropathic pain and peripheral nerve injury, administered via local injection. miR-21 and BDNF signalling - confirmed per batch via RNA-seq - are the key cargo mediators identified in this literature.
BEXO·NEURO is enriched with neuroprotective, neurotrophic, and immunomodulatory cargo confirmed via RNA-seq per batch. The following cargo categories have been identified.